Telix Pharmaceuticals Ltd has released a press release.
Illuccix European Marketing Authorisation Application Update
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- FDA approval of expanded indication of Illuccix in the US
- 2022 Full Year Results Presentation
- Appendix 4E and 2022 Annual Report
- 2022 Full Year Results Release
- Telix Full Year Results and Investor Conference Call Details
Later from Telix Pharmaceuticals
- Telix Preclinical Development of Radiolabelled Olaratumab
- Appendix 4C and Activities Report - March 2023 Quarter
- Q1 2023 Business update to accompany quarterly results
- Telix Accelerates AI Development with Dedicaid Acquisition
- Presentation to Accompany AI Development Program Update
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals